Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data

Christopher L.l. Morgan; Paul Emery; Duncan Porter; Alan Reynolds; Adam Young; Helen Boyd; Chris D. Poole; Craig J. Currie

doi:10.1093/rheumatology/ket333

Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data

Christopher L.l. Morgan, Paul Emery, Duncan Porter, Alan Reynolds, Adam Young, Helen Boyd, Chris D. Poole, Craig J. Currie

Research output: Contribution to journal › Article › peer-review

56 Citations (Scopus)

Abstract

The objective of this study was to examine the long-term safety of etanercept (ETN) in comparison with conventional DMARDs in a large observational cohort of RA patients in the UK.

Original language	English
Pages (from-to)	186-94
Number of pages	9
Journal	Rheumatology
Volume	53
Issue number	1
Early online date	18 Oct 2013
DOIs	https://doi.org/10.1093/rheumatology/ket333
Publication status	Published - Jan 2014

Keywords

Antirheumatic Agents
Arthritis, Rheumatoid
Female
Follow-Up Studies
Forecasting
Great Britain
Humans
Immunoglobulin G
Male
Middle Aged
Prospective Studies
Receptors, Tumor Necrosis Factor
Survival Rate
Treatment Outcome
Tumor Necrosis Factor-alpha

Access to Document

10.1093/rheumatology/ket333

Cite this

@article{5a5011c9ec5f4738b655a850ed19cfdf,

title = "Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data",

abstract = "The objective of this study was to examine the long-term safety of etanercept (ETN) in comparison with conventional DMARDs in a large observational cohort of RA patients in the UK.",

keywords = "Antirheumatic Agents, Arthritis, Rheumatoid, Female, Follow-Up Studies, Forecasting, Great Britain, Humans, Immunoglobulin G, Male, Middle Aged, Prospective Studies, Receptors, Tumor Necrosis Factor, Survival Rate, Treatment Outcome, Tumor Necrosis Factor-alpha",

author = "Morgan, \{Christopher L.l.\} and Paul Emery and Duncan Porter and Alan Reynolds and Adam Young and Helen Boyd and Poole, \{Chris D.\} and Currie, \{Craig J.\}",

year = "2014",

month = jan,

doi = "10.1093/rheumatology/ket333",

language = "English",

volume = "53",

pages = "186--94",

journal = "Rheumatology",

issn = "1462-0324",

publisher = "Oxford University Press (OUP)",

number = "1",

}

TY - JOUR

T1 - Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs

T2 - long-term safety and survival using prospective, observational data

AU - Morgan, Christopher L.l.

AU - Emery, Paul

AU - Porter, Duncan

AU - Reynolds, Alan

AU - Young, Adam

AU - Boyd, Helen

AU - Poole, Chris D.

AU - Currie, Craig J.

PY - 2014/1

Y1 - 2014/1

N2 - The objective of this study was to examine the long-term safety of etanercept (ETN) in comparison with conventional DMARDs in a large observational cohort of RA patients in the UK.

AB - The objective of this study was to examine the long-term safety of etanercept (ETN) in comparison with conventional DMARDs in a large observational cohort of RA patients in the UK.

KW - Antirheumatic Agents

KW - Arthritis, Rheumatoid

KW - Female

KW - Follow-Up Studies

KW - Forecasting

KW - Great Britain

KW - Humans

KW - Immunoglobulin G

KW - Male

KW - Middle Aged

KW - Prospective Studies

KW - Receptors, Tumor Necrosis Factor

KW - Survival Rate

KW - Treatment Outcome

KW - Tumor Necrosis Factor-alpha

U2 - 10.1093/rheumatology/ket333

DO - 10.1093/rheumatology/ket333

M3 - Article

C2 - 24140761

SN - 1462-0324

VL - 53

SP - 186

EP - 194

JO - Rheumatology

JF - Rheumatology

IS - 1

ER -

Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data

Abstract

Keywords

Access to Document

Fingerprint

Cite this